Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial
Authors:
Open Access
- 16 May 2025
- journal article
- research article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (7) , 102734
Abstract
No abstract availableKeywords
Funding Information
- ViiV Healthcare
This publication has 7 references indexed in Scilit:
- Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96HIV Medicine, 2023
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialThe Lancet HIV, 2023
- Factors Associated with Treatment Satisfaction Among People Living with HIV in Japan and Other Selected Countries: Examination of the Intertwined Roles of Medication, Patient, and Provider CharacteristicsAIDS and Behavior, 2021
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyThe Lancet, 2020
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR TrialsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2020
- Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 WeeksAIDS and Behavior, 2020
- HIV-1 Antiretroviral Drug TherapyCold Spring Harbor Perspectives in Medicine, 2012